Arcutis Biotherapeutics, Inc. (ARQT) Profit Margins
Over the twelve months to 2026-06-30, Arcutis Biotherapeutics, Inc. (ARQT) had gross margin 91.1%, operating margin 7.4%, net margin 6.1%, free cash flow margin 8.4%, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
ARQTArcutis Biotherapeutics, Inc.Follow ARQT — free
—
Price chart with a free account
- Market cap
- 3.9B
- P/E TTM
- 148.6
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 4 Nov, in 11 days
| Line | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|
| Gross margin | — | 91.6% | 90.3% | 90.2% | 91.1% | |
| Operating margin | -8183.0% | -404.5% | -65.3% | -3.3% | 7.4% | |
| Net margin | -8449.8% | -439.8% | -71.3% | -4.3% | 6.1% | |
| FCF margin | -7000.8% | -415.2% | -57.1% | -1.7% | 8.4% |
USD millions · SEC XBRL
Arcutis Biotherapeutics, Inc. — questions
- What is Arcutis Biotherapeutics, Inc.'s gross margin?
- 91.1% over the twelve months to 2026-06-30.
- What is Arcutis Biotherapeutics, Inc.'s operating margin?
- 7.4% over the twelve months to 2026-06-30.
- What is Arcutis Biotherapeutics, Inc.'s net profit margin?
- 6.1% over the twelve months to 2026-06-30.
Every figure on this page comes from Arcutis Biotherapeutics, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.